Next Article in Journal
Quantum Chemical Design Guidelines for Absorption and Emission Color Tuning of fac-Ir(ppy)3 Complexes
Next Article in Special Issue
[18F]fallypride-PET/CT Analysis of the Dopamine D2/D3 Receptor in the Hemiparkinsonian Rat Brain Following Intrastriatal Botulinum Neurotoxin A Injection
Previous Article in Journal
Phenolic Compounds from Belamcanda chinensis Seeds
Previous Article in Special Issue
Investigation of an 18F-labelled Imidazopyridotriazine for Molecular Imaging of Cyclic Nucleotide Phosphodiesterase 2A
Article Menu
Issue 3 (March) cover image

Export Article

Open AccessReview
Molecules 2018, 23(3), 581; https://doi.org/10.3390/molecules23030581

Progress in Targeted Alpha-Particle Therapy. What We Learned about Recoils Release from In Vivo Generators

1
Czech Technical University in Prague, Faculty of Nuclear Sciences and Physical Engineering, Prague CZ-11519, Czech Republic
2
Vernadsky Institute of Geochemistry and Analytical Chemistry, Moscow 119991, Russia
*
Author to whom correspondence should be addressed.
Received: 17 January 2018 / Revised: 26 February 2018 / Accepted: 28 February 2018 / Published: 5 March 2018
(This article belongs to the Special Issue Current Aspects of Radiopharmaceutical Chemistry)
Full-Text   |   PDF [2385 KB, uploaded 5 March 2018]   |  

Abstract

This review summarizes recent progress and developments as well as the most important pitfalls in targeted alpha-particle therapy, covering single alpha-particle emitters as well as in vivo alpha-particle generators. It discusses the production of radionuclides like 211At, 223Ra, 225Ac/213Bi, labelling and delivery employing various targeting vectors (small molecules, chelators for alpha-emitting nuclides and their biomolecular targets as well as nanocarriers), general radiopharmaceutical issues, preclinical studies, and clinical trials including the possibilities of therapy prognosis and follow-up imaging. Special attention is given to the nuclear recoil effect and its impacts on the possible use of alpha emitters for cancer treatment, proper dose estimation, and labelling chemistry. The most recent and important achievements in the development of alpha emitters carrying vectors for preclinical and clinical use are highlighted along with an outlook for future developments. View Full-Text
Keywords: targeted alpha therapy; nuclear recoil; in vivo generators; radium; 223Ra; actinium; astatine; bismuth; alpha particle; decay targeted alpha therapy; nuclear recoil; in vivo generators; radium; 223Ra; actinium; astatine; bismuth; alpha particle; decay
Figures

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Kozempel, J.; Mokhodoeva, O.; Vlk, M. Progress in Targeted Alpha-Particle Therapy. What We Learned about Recoils Release from In Vivo Generators. Molecules 2018, 23, 581.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top